Navigation Links
Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors

SAN DIEGO, March 31 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease, today announced the appointment of two additional members to its board of directors: Dennis M. Fenton, Ph.D. and Stephen W. Kaldor, Ph.D.

Dr. Fenton has 30 years of pharmaceutical and biotechnology experience, including over two decades at Amgen where he played an instrumental role in the development of the company into a global, fully-integrated, multi-billion dollar organization. Fenton's broad background includes executive leadership roles in manufacturing, process development, sales and marketing, operations and quality control. His most recent role at Amgen was as Executive Vice President of Operations.

Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

"Dennis is a biotechnology pioneer," said chief executive officer, Bob Baltera. "His experience and insight from his years at Amgen will be extremely useful for Amira as we plan our future. In addition to Dennis, we are also very pleased that Steve Kaldor will join our board of directors. Steve's experience in successful start-up companies further deepens our pool of experience and knowledge and I'm sure he will serve as a great partner for us."

Dr. Kaldor is currently president and chief executive officer of Ambrx, a private biotechnology company focused on the development of next-generation, protein-based medicines. Prior to joining Ambrx, Kaldor served as president and chief scientific officer of Syrrx, a structure-based drug discovery company, which he led through its $270 million acquisition by Takeda in 2005. He also spent over twelve years in various research and development roles at Eli Lilly and is a co-inventor of Viracept(R), a marketed AIDS drug.

Kaldor holds a B.S. in Chemistry from Columbia University and a Ph.D. in Organic Chemistry from Harvard University.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.

In February 2008, Amira Pharmaceuticals and GlaxoSmithKline entered a global agreement for Amira's FLAP inhibitor program. The deal follows positive phase 1 data from novel product candidate AM103 for the oral treatment of respiratory disease.

Amira has raised $40 million to date from investors including Novo A/S (Copenhagen, Denmark), Avalon Ventures (San Diego, CA), Prospect Ventures (Palo Alto, CA) and Versant Ventures (Menlo Park, CA). For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dennis Joyce Joins Executive and Board Search Firm Hodge / Niederer / Cariani / Lindsay
2. Bacchus Vascular Names Dennis Rosenberg as Vice President of Marketing
3. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
4. TIGroup Names Dennis M. Smith as Chief Financial Officer
5. Dr. Steve Liu, CEO of Ingenious Med, Joins Benchmarks Committee at SHM
6. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
7. Northwestern Memorial Hospitals Steven J. Stryker MD Unveils Campaign With Empower Public Relations
8. Stevens UV expert at Science-on-Saturday program
9. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse
10. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
11. Play by Steve Nash, Assisted by Milk
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... Crystal Lake, IL (PRWEB) , ... November 25, 2015 , ... ... pleased to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto ... the case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for ... , For 65 years, Brillianteen has been a treasured tradition for ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
Breaking Medicine Technology: